Spots Global Cancer Trial Database for bruton's tyrosine kinase
Every month we try and update this database with for bruton's tyrosine kinase cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer | NCT05106296 | Ependymoma Medulloblastoma Glioblastoma Primary Brain T... | Ibrutinib Indoximod Cyclophosphamid... Etoposide | 12 Years - 25 Years | Augusta University | |
| A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL | NCT03740529 | Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Marginal Zone L... B-cell Lymphoma Small Lymphocyt... | Pirtobrutinib Venetoclax Rituximab | 18 Years - | Eli Lilly and Company | |
| Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma | NCT01962792 | Multiple Myelom... | Ibrutinib Carfilzomib Dexamethasone | 18 Years - | Pharmacyclics LLC. | |
| Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia | NCT04624906 | Waldenstrom Mac... | Acalabrutinib Bendamustine Rituximab | 18 Years - | Sunnybrook Health Sciences Centre | |
| Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer | NCT05106296 | Ependymoma Medulloblastoma Glioblastoma Primary Brain T... | Ibrutinib Indoximod Cyclophosphamid... Etoposide | 12 Years - 25 Years | Augusta University | |
| A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies | NCT05131022 | Chronic Lymphoc... Small Lymphocyt... Diffuse Large B... Follicular Lymp... Mantle Cell Lym... Marginal Zone L... Waldenstrom Mac... Primary Central... | NX-5948 | 18 Years - | Nurix Therapeutics, Inc. | |
| Safety and Efficacy Study of a BTK Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma | NCT01325701 | Diffuse Large C... | ibrutinib | 18 Years - | Pharmacyclics LLC. | |
| Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma | NCT02112526 | Activated B-cel... | Acalabrutinib | 18 Years - 130 Years | Acerta Pharma BV | |
| Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma | NCT02548962 | Multiple Myelom... | Ibrutinib Pomalidomide Dexamethasone Placebo | 18 Years - 100 Years | Pharmacyclics LLC. | |
| Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma | NCT01478581 | Multiple Myelom... | PCI-32765 Dexamethasone | 18 Years - | Pharmacyclics LLC. | |
| Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma | NCT02902965 | Multiple Myelom... | Ibrutinib Bortezomib Dexamethasone | 18 Years - | Pharmacyclics Switzerland GmbH | |
| VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib | NCT03400176 | Chronic Lymphoc... | VAY736 ibrutinib | 18 Years - | Novartis | |
| Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma | NCT01478581 | Multiple Myelom... | PCI-32765 Dexamethasone | 18 Years - | Pharmacyclics LLC. | |
| LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies | NCT05990465 | Non Hodgkin Lym... Diffuse Large B... Follicular Lymp... Marginal Zone L... Mantle Cell Lym... Burkitt Lymphom... | Pirtobrutinib LV20.19 CAR T c... | 18 Years - 81 Years | Medical College of Wisconsin | |
| Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma | NCT02548962 | Multiple Myelom... | Ibrutinib Pomalidomide Dexamethasone Placebo | 18 Years - 100 Years | Pharmacyclics LLC. | |
| Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma | NCT00849654 | B-Cell Lymphoma B-Cell Leukemia | PCI-32765 | 18 Years - | Pharmacyclics LLC. | |
| Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia | NCT04624906 | Waldenstrom Mac... | Acalabrutinib Bendamustine Rituximab | 18 Years - | Sunnybrook Health Sciences Centre | |
| Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma | NCT01478581 | Multiple Myelom... | PCI-32765 Dexamethasone | 18 Years - | Pharmacyclics LLC. | |
| A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL | NCT03740529 | Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Marginal Zone L... B-cell Lymphoma Small Lymphocyt... | Pirtobrutinib Venetoclax Rituximab | 18 Years - | Eli Lilly and Company | |
| Safety and Efficacy Study of a BTK Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma | NCT01325701 | Diffuse Large C... | ibrutinib | 18 Years - | Pharmacyclics LLC. | |
| Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL) | NCT01292135 | B-cell Chronic ... Small Lymphocyt... | PCI-32765 | 18 Years - | Pharmacyclics LLC. | |
| A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies | NCT04830137 | Chronic Lymphoc... Small Lymphocyt... Waldenstrom Mac... Mantle Cell Lym... Marginal Zone L... Follicular Lymp... Diffuse Large B... Primary Central... | NX-2127 | 18 Years - | Nurix Therapeutics, Inc. | |
| Safety of PCI-32765 in Chronic Lymphocytic Leukemia | NCT01105247 | B-cell Chronic ... Small Lymphocyt... | PCI-32765 | 18 Years - | Pharmacyclics LLC. | |
| Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL) | NCT01292135 | B-cell Chronic ... Small Lymphocyt... | PCI-32765 | 18 Years - | Pharmacyclics LLC. | |
| Safety and Efficacy Study of a BTK Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma | NCT01325701 | Diffuse Large C... | ibrutinib | 18 Years - | Pharmacyclics LLC. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
